Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

127
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
127
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

363
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
363
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

116
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
116
Pharmacovigilance01:19

Pharmacovigilance

2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

996
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
996
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Personality traits and career preferences of pharmacy students: a cross-sectional study at Kuwait University.

BMC medical education·2026
Same author

Empowering competence: A program-wide active learning framework for a pharmacy program.

American journal of pharmaceutical education·2024
Same author

Expert consensus for a national essential antidote list: E-Delphi method.

PloS one·2022
Same author

Evolving to Objective Structured Clinical Exams (OSCE): Transitional experience in an undergraduate pharmacy program in Kuwait.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society·2021
Same author

Perspectives of primary care physicians and pharmacists on interprofessional collaboration in Kuwait: A quantitative study.

PloS one·2020
Same author

Availability of Antidotes in Kuwait: A National Audit.

The Journal of emergency medicine·2019

Related Experiment Video

Updated: May 2, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.9K

Pharmacy practice-based research networks: do pharmacists need them?

Samuel Koshy1

  • 1Department of Pharmacy Practice, Faculty of Pharmacy, Kuwait University, Safat, Kuwait.

The International Journal of Pharmacy Practice
|March 12, 2014
PubMed
Summary

Pharmacy practice-based research networks (PBRNs) are essential for large-scale studies on pharmacist-provided patient care. Global engagement is needed now to develop these vital research networks.

Keywords:
pharmacistpharmacypractice-based research networksresearch

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K
Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management
03:53

Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management

Published on: March 15, 2024

3.5K

Related Experiment Videos

Last Updated: May 2, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.9K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K
Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management
03:53

Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management

Published on: March 15, 2024

3.5K

Area of Science:

  • Health Services Research
  • Pharmaceutical Sciences
  • Implementation Science

Background:

  • Evidence generation for pharmacist-led patient care services is crucial.
  • Current research infrastructure may not adequately support large, multicenter studies.
  • The need for robust data on the impact of pharmacy services is increasing.

Purpose of the Study:

  • To emphasize the critical need for establishing pharmacy practice-based research networks (PBRNs).
  • To advocate for the development of PBRNs to advance pharmaceutical practice and patient care.
  • To call for global collaboration among pharmacists in building PBRNs.

Main Methods:

  • This article presents a perspective on the necessity and potential benefits of PBRNs.
  • It synthesizes the current landscape and future requirements for practice-based research in pharmacy.
  • No primary data collection or analysis was performed; it is a conceptual and advocacy piece.

Main Results:

  • Large-scale, multicenter research projects are required to generate evidence for patient care services provided by pharmacists.
  • Pharmacy PBRNs are identified as a key facilitator for conducting such essential research.
  • The development of PBRNs will enhance the capacity for evidence-based practice in pharmacy.

Conclusions:

  • There is a significant and growing demand for the establishment of pharmacy PBRNs.
  • The current global context is opportune for pharmacists to actively participate in developing these networks.
  • Developing PBRNs is a strategic imperative for advancing the profession and improving patient outcomes.